Literature DB >> 10854555

Immunohistochemical expression of vascular endothelial growth factor can predict response to 5-fluorouracil and cisplatin in patients with gastric adenocarcinoma.

H Takiuchi1, I Hirata, S Kawabe, Y Egashira, K Katsu.   

Abstract

The combination of 5-fluorouracil (5-FU) and cisplatin is used most commonly for gastric carcinoma. Recent studies have indicated that vascular endothelial growth factor (VEGF) is related to drug delivery through angiogenesis and vascular permeability. In this study, we evaluated the efficacy and toxicity of continuous infusion of 5-FU and low dose cisplatin infusion as first-line treatment in patients with unresectable gastric adenocarcinoma. We also examined the relationship between chemotherapy response and immunohistochemical expression of VEGF in the biopsy samples of gastric primary. All 30 patients enrolled in this study were assessable for response, adverse reactions, and VEGF expression. The regimen consisted of 5-FU (350 mg/m2/day every day by continuous venous infusion) and low dose cisplatin (7 mg/m2/day by drip infusion over 1 h on days 1-5 every week). This treatment was repeated weekly for 3 consecutive weeks. Four weeks after the second cycle, mesurable lesions were estimated for response. An overall response rate was 46.7% (14/30). Patients with intestinal histologic type (10/12) and good performance status ([PS], 13/18) showed good response rate (83.3%, and 72.2%, respectively) compared to patients with diffuse histologic type (4/18) and poor PS [(1/12) 22.2%, and 8. 3%, respectively]. The response rate of VEGF-positive cases and VEGF-negative cases was 75% (12/16), and 16.7% (2/14), respectively. Multivarite analysis revealed that VEGF-positive and good PS had a significant impact on chemotherapy response in this treatment. The most common garde 3 or higher toxicities were myelosuppression (30%) and diarrhea (13.3%). Continuous infusion of 5-FU and low dose cisplatin infusion is an effective treatment for patients with unresectable gastric carcinoma, and VEGF expression may be a useful predictor of chemotherapy response in this regimen.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10854555     DOI: 10.3892/or.7.4.841

Source DB:  PubMed          Journal:  Oncol Rep        ISSN: 1021-335X            Impact factor:   3.906


  7 in total

1.  Is pretreatment endoscopic biopsy a good predictor of signet ring cell histology in gastric carcinoma?

Authors:  Guillaume Piessen; David Amielh; Mathieu Messager; Edouard Vinatier; Emmanuelle Leteurtre; Jean Pierre Triboulet; Christophe Mariette
Journal:  World J Surg       Date:  2012-02       Impact factor: 3.352

2.  A systematic review and meta-analysis of randomized trials on the role of targeted therapy in the management of advanced gastric cancer: Evidence does not translate?

Authors:  Domenico Ciliberto; Nicoletta Staropoli; Francesca Caglioti; Simona Gualtieri; Lucia Fiorillo; Silvia Chiellino; Antonina Maria De Angelis; Francesco Mendicino; Cirino Botta; Michele Caraglia; Pierfrancesco Tassone; Pierosandro Tagliaferri
Journal:  Cancer Biol Ther       Date:  2015-06-10       Impact factor: 4.742

3.  Comparison between signet-ring cell carcinoma and non-signet-ring cell carcinoma of the stomach: clinicopathological parameters, epidemiological data, outcome, and prognosis-a cohort study of 123 patients from a non-endemic country.

Authors:  Haithem Zaafouri; Raja Jouini; Nizar Khedhiri; Fatma Khanchel; Mona Cherif; Meryam Mesbahi; Aziz Daghmouri; Wiem Mahmoudi; Soumaya Akremi; Meriam Sabbah; Yazid Benzarti; Dhafer Hadded; Dalila Gargouri; Mourad Ben Bader; Anis Ben Maamer
Journal:  World J Surg Oncol       Date:  2022-07-20       Impact factor: 3.253

Review 4.  Clinical significance of angiogenesis in gastrointestinal cancers: a target for novel prognostic and therapeutic approaches.

Authors:  Ronnie Tung-Ping Poon; Sheung-Tat Fan; John Wong
Journal:  Ann Surg       Date:  2003-07       Impact factor: 12.969

5.  VEGFA and VEGFR2 RNAscope determination in gastric cancer.

Authors:  Roberto Tamma; Tiziana Annese; Simona Ruggieri; Andrea Marzullo; Beatrice Nico; Domenico Ribatti
Journal:  J Mol Histol       Date:  2018-05-14       Impact factor: 2.611

6.  Phase II/III multicentre randomised controlled trial evaluating a strategy of primary surgery and adjuvant chemotherapy versus peri-operative chemotherapy for resectable gastric signet ring cell adenocarcinomas - PRODIGE 19 - FFCD1103 - ADCI002.

Authors:  Guillaume Piessen; Mathieu Messager; Karine Le Malicot; William B Robb; Frédéric Di Fiore; Marie Guilbert; Marie Moreau; Véronique Christophe; Antoine Adenis; Christophe Mariette
Journal:  BMC Cancer       Date:  2013-06-10       Impact factor: 4.430

7.  Analysis of the mRNA expression of chemotherapy-related genes in colorectal carcinoma using the danenberg tumor profile method.

Authors:  Shin Sasaki; Toshiyuki Watanabe; Hiroshi Nakayama
Journal:  J Oncol       Date:  2013-03-16       Impact factor: 4.375

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.